Drug Trial Radar · NCT07686484
A Trial of HRS-3095 in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Oct 16, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Atridia Pty Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 7, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess safety, PK, Pharmacodynamic profile of a single dose of HRS-3095 in healthy participants
Conditions
- Chronic Spontaneous Urticaria
Interventions
HRS-3095Drug
Single dose HRS-3095 /placebo given orally - Dose level 1
HRS-3095Drug
Single dose HRS-3095 /placebo given orally - Dose level 2
HRS-3095Drug
Single dose HRS-3095 /placebo given orally - Dose level 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse EventsTime frame: Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Veritus Research
Bayswater, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.